Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Eli Lilly · Phase 2 · Not yet recruiting · Enrollment 224

NCT06732245

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebo Comparator: Placebon/rn/rn/rn/r
Placebo + Tirzepatide 5 mgn/rn/rn/rn/r
Placebo + Tirzepatide 10 mgn/rn/rn/rn/r
NA-931 60mg to NA-931 150 mg + no Tirzepatiden/rn/rn/rn/r
NA-931 60 mg + Tirzepatide 5 mgn/rn/rn/rn/r
NA-931 120 mg + Tirzepatide 5 mgn/rn/rn/rn/r
NA-931 150 mg + no Tirzepatiden/rn/rn/rn/r
NA-931 150 mg + Tirzepatide 2.5 mgn/rn/rn/rn/r
NA-931 150 mg + Tirzepatide 5 mgn/rn/rn/rn/r

Not shown

  • Placebo Comparator: Placebo: endpoint not reported
  • Placebo + Tirzepatide 5 mg: endpoint not reported
  • Placebo + Tirzepatide 10 mg: endpoint not reported
  • NA-931 60mg to NA-931 150 mg + no Tirzepatide: endpoint not reported
  • NA-931 60 mg + Tirzepatide 5 mg: endpoint not reported
  • NA-931 120 mg + Tirzepatide 5 mg: endpoint not reported
  • NA-931 150 mg + no Tirzepatide: endpoint not reported
  • NA-931 150 mg + Tirzepatide 2.5 mg: endpoint not reported
  • NA-931 150 mg + Tirzepatide 5 mg: endpoint not reported